Olivier Rascol

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3070774/publications.pdf

Version: 2024-02-01

252 papers	29,837 citations	7069 78 h-index	5227 165 g-index
278 all docs	278 docs citations	278 times ranked	21511 citing authors

#	Article	IF	Citations
1	Movement Disorder Societyâ€sponsored revision of the Unified Parkinson's Disease Rating Scale (MDSâ€UPDRS): Scale presentation and clinimetric testing results. Movement Disorders, 2008, 23, 2129-2170.	2.2	4,796
2	MovementDisorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations TheMovementDisorder Society Task Force on rating scales for Parkinson's disease. Movement Disorders, 2004, 19, 1020-1028.	2.2	1,739
3	A Five-Year Study of the Incidence of Dyskinesia in Patients with Early Parkinson's Disease Who Were Treated with Ropinirole or Levodopa. New England Journal of Medicine, 2000, 342, 1484-1491.	13.9	1,467
4	Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Movement Disorders, 2007, 22, 41-47.	2.2	1,097
5	A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease. New England Journal of Medicine, 2009, 361, 1268-1278.	13.9	830
6	Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Annals of Neurology, 2003, 54, 93-101.	2.8	820
7	Depression rating scales in Parkinson's disease: Critique and recommendations. Movement Disorders, 2007, 22, 1077-1092.	2.2	583
8	Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). Movement Disorders, 2004, 19, 1391-1402.	2.2	481
9	The Movement Disorder Society Evidenceâ€Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease. Movement Disorders, 2011, 26, S2-41.	2.2	479
10	Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2010, 9, 573-580.	4.9	476
11	The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurology, The, 2013, 12, 264-274.	4.9	426
12	Magnetic resonance imaging markers of Parkinsonâ€™s disease nigrostriatal signature. Brain, 2010, 133, 3423-3433.	3.7	374
13	Factors predictive of the development of Levodopaâ€induced dyskinesia and wearingâ€off in Parkinson's disease. Movement Disorders, 2013, 28, 1064-1071.	2.2	374
14	Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial. Lancet, The, 2014, 383, 1138-1146.	6.3	368
15	Priorities in Parkinson's disease research. Nature Reviews Drug Discovery, 2011, 10, 377-393.	21.5	364
16	Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurology, The, 2007, 6, 513-520.	4.9	359
17	Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke. Annals of Neurology, 2001, 50, 718-729.	2.8	345
18	Loss of VPS13C Function in Autosomal-Recessive Parkinsonism Causes Mitochondrial Dysfunction and Increases PINK1/Parkin-Dependent Mitophagy. American Journal of Human Genetics, 2016, 98, 500-513.	2.6	333

#	Article	IF	Citations
19	Levodopa in the treatment of Parkinson's disease: Current controversies. Movement Disorders, 2004, 19, 997-1005.	2.2	331
20	Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDEâ€PD study. Annals of Neurology, 2010, 68, 18-27.	2.8	330
21	LRRK2 in Parkinson disease: challenges of clinical trials. Nature Reviews Neurology, 2020, 16, 97-107.	4.9	281
22	How much phenotypic variation can be attributed toparkingenotype?. Annals of Neurology, 2003, 54, 176-185.	2.8	271
23	Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet, The, 2002, 359, 1589-1598.	6.3	266
24	Ropinirole in the treatment of early Parkinson's disease: A 6-month interim report of a 5-year levodopa-controlled study. Movement Disorders, 1998, 13, 39-45.	2.2	262
25	Chronic pain in Parkinson's disease: The crossâ€sectional French DoPaMiP survey. Movement Disorders, 2008, 23, 1361-1369.	2.2	257
26	Limitations of current Parkinson's disease therapy. Annals of Neurology, 2003, 53, S3-S15.	2.8	250
27	Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double-blind placebo-controlled trial. Movement Disorders, 2007, 22, 179-186.	2.2	249
28	Prevalence, Determinants, and Effect on Quality of Life of Freezing of Gait in Parkinson Disease. JAMA Neurology, 2014, 71, 884.	4.5	241
29	Supplementary and Primary Sensory Motor Area Activity in Parkinson's Disease. Archives of Neurology, 1992, 49, 144.	4.9	222
30	Tenâ€year followâ€up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Movement Disorders, 2007, 22, 2409-2417.	2.2	221
31	Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurology, The, 2016, 15, 154-165.	4.9	219
32	Scales to assess sleep impairment in Parkinson's disease: Critique and recommendations. Movement Disorders, 2010, 25, 2704-2716.	2.2	214
33	Presentation, diagnosis, and management of multiple system atrophy in Europe: Final analysis of the European multiple system atrophy registry. Movement Disorders, 2010, 25, 2604-2612.	2.2	205
34	Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurology, The, 2018, 17, 749-759.	4.9	203
35	Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease. Movement Disorders, 2010, 25, 805-822.	2.2	193
36	A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurology, The, 2011, 10, 415-423.	4.9	192

#	Article	IF	Citations
37	Continuous dopamine-receptor stimulation in early Parkinson's disease. Trends in Neurosciences, 2000, 23, S117-S126.	4.2	185
38	Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nature Reviews Drug Discovery, 2018, 17, 804-822.	21.5	178
39	Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial. Lancet Neurology, The, 2013, 12, 747-755.	4.9	175
40	Longitudinal analysis of impulse control disorders in Parkinson disease. Neurology, 2018, 91, e189-e201.	1.5	175
41	A mutation at codon 279 (N279K) in exon 10 of the Tau gene causes a tauopathy with dementia and supranuclear palsy. Acta Neuropathologica, 1999, 98, 62-77.	3.9	174
42	Mapping of Spinocerebellar Ataxia 13 to Chromosome 19q13.3-q13.4 in a Family with Autosomal Dominant Cerebellar Ataxia and Mental Retardation. American Journal of Human Genetics, 2000, 67, 229-235.	2.6	166
43	Milestones in Parkinson's disease therapeutics. Movement Disorders, 2011, 26, 1072-1082.	2.2	162
44	Multicenter, Open-Label, Trial of Sarizotan in Parkinson Disease Patients With Levodopa-Induced Dyskinesias (the SPLENDID Study). Clinical Neuropharmacology, 2004, 27, 58-62.	0.2	161
45	Neural Substrate for the Effects of Passive Training on Sensorimotor Cortical Representation: A Study with Functional Magnetic Resonance Imaging in Healthy Subjects. Journal of Cerebral Blood Flow and Metabolism, 2000, 20, 478-484.	2.4	153
46	Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial. Lancet Neurology, The, 2012, 11, 589-596.	4.9	150
47	Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations. JAMA Neurology, 2017, 74, 197.	4.5	146
48	Within-Session and Between-Session Reproducibility of Cerebral Sensorimotor Activation: A Testâ€“Retest Effect Evidenced with Functional Magnetic Resonance Imaging. Journal of Cerebral Blood Flow and Metabolism, 2001, 21, 592-607.	2.4	145
49	Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6-month interim report of a 3-year study. Movement Disorders, 1998, 13, 46-51.	2.2	135
50	Prediction of cognition in Parkinson's disease with a clinicalâ€“genetic score: a longitudinal analysis of nine cohorts. Lancet Neurology, The, 2017, 16, 620-629.	4.9	131
51	Selecting deep brain stimulation or infusion therapies in advanced Parkinsonâ€™s disease: an evidence-based review. Journal of Neurology, 2013, 260, 2701-2714.	1.8	128
52	Drugâ€induced parkinsonism: A review of 17 years' experience in a regional pharmacovigilance center in France. Movement Disorders, 2011, 26, 2226-2231.	2.2	122
53	AFQ056 in Parkinson patients with levodopaâ€induced dyskinesia: 13â€week, randomized, doseâ€finding study. Movement Disorders, 2013, 28, 1838-1846.	2.2	122
54	Withdrawing amantadine in dyskinetic patients with Parkinson disease. Neurology, 2014, 82, 300-307.	1.5	122

#	Article	IF	Citations
55	Orthostatic Hypotension in Patients with Parkinson??s Disease. Drugs and Aging, 2001, 18, 495-505.	1.3	115
56	Placebo influences on dyskinesia in Parkinson's disease. Movement Disorders, 2008, 23, 700-707.	2.2	111
57	A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease. Movement Disorders, 2016, 31, 1373-1380.	2.2	111
58	A Single Dose of the Serotonin Neurotransmission Agonist Paroxetine Enhances Motor Output: Double-Blind, Placebo-Controlled, fMRI Study in Healthy Subjects. NeuroImage, 2002, 15, 26-36.	2.1	107
59	Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson's disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial. Lancet Neurology, The, 2018, 17, 223-231.	4.9	105
60	Subthalamic Nucleus Stimulation Reduces Abnormal Motor Cortical Overactivity in Parkinson Disease. Archives of Neurology, 2004, 61, 1307-13.	4.9	104
61	Object naming and action-verb generation in Parkinson's disease: A fMRI study. Cortex, 2009, 45, 960-971.	1.1	103
62	Prolonged-release oxycodoneâ€“naloxone for treatment of severe pain in patients with Parkinson's disease (PANDA): a double-blind, randomised, placebo-controlled trial. Lancet Neurology, The, 2015, 14, 1161-1170.	4.9	102
63	Volume and iron content in basal ganglia and thalamus. Human Brain Mapping, 2009, 30, 2667-2675.	1.9	98
64	Antivertigo Medications and Drug-Induced Vertigo. Drugs, 1995, 50, 777-791.	4.9	96
65	Dopamine Receptor Agonists for the Treatment of Early or Advanced ParkinsonÊ¼s Disease. CNS Drugs, 2010, 24, 941-968.	2.7	96
66	¹²³Iâ€metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders. Movement Disorders, 2009, 24, S732-41.	2.2	95
67	New treatments for levodopaâ€induced motor complications. Movement Disorders, 2015, 30, 1451-1460.	2.2	95
68	Iron as a therapeutic target for Parkinson's disease. Movement Disorders, 2018, 33, 568-574.	2.2	94
69	Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias. Parkinsonism and Related Disorders, 2014, 20, 947-956.	1.1	93
70	Task force report on scales to assess dyskinesia in Parkinson's disease: Critique and recommendations. Movement Disorders, 2010, 25, 1131-1142.	2.2	90
71	Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial. Lancet Neurology, The, 2015, 14, 145-152.	4.9	90
72	Randomized, doubleâ€blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease. Movement Disorders, 2010, 25, 2542-2549.	2.2	87

#	Article	IF	Citations
73	Multimodal MRI assessment of nigro-striatal pathway in multiple system atrophy and Parkinson disease. Movement Disorders, 2016, 31, 325-334.	2.2	87
74	Sleep Attacks and Antiparkinsonian Drugs: A Pilot Prospective Pharmacoepidemiologic Study. Clinical Neuropharmacology, 2001, 24, 181-183.	0.2	85
75	Prevalence and Pharmacological Factors Associated With Impulse-Control Disorder Symptoms in Patients With Parkinson Disease. Clinical Neuropharmacology, 2012, 35, 261-265.	0.2	85
76	Effect of Side and Rate of Stimulation on Cerebral Blood Flow Changes in Motor Areas during Finger Movements in Humans. Journal of Cerebral Blood Flow and Metabolism, 1993, 13, 639-645.	2.4	83
77	Parkinson's disease and local atrophy in subcortical nuclei: insight from shape analysis. Neurobiology of Aging, 2015, 36, 424-433.	1.5	81
78	Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease. JAMA Neurology, 2015, 72, 1491.	4.5	80
79	Unmasking levodopa resistance in Parkinson's disease. Movement Disorders, 2016, 31, 1602-1609.	2.2	80
80	A Randomized Controlled Exploratory Pilot Study to Evaluate the Effect of Rotigotine Transdermal Patch on Parkinson's Disease-Associated Chronic Pain. Journal of Clinical Pharmacology, 2016, 56, 852-861.	1.0	79
81	Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease. Movement Disorders, 1994, 9, 437-440.	2.2	78
82	MRI supervised and unsupervised classification of Parkinson's disease and multiple system atrophy. Movement Disorders, 2018, 33, 600-608.	2.2	77
83	Which dyskinesia scale best detects treatment response?. Movement Disorders, 2013, 28, 341-346.	2.2	76
84	Opicapone for the treatment of Parkinson's disease: A review of a new licensed medicine. Movement Disorders, 2018, 33, 1528-1539.	2.2	73
85	Modulation of behavior and cortical motor activity in healthy subjects by a chronic administration of a serotonin enhancer. NeuroImage, 2005, 27, 299-313.	2.1	72
86	Cerebral Functional Magnetic Resonance Imaging Activation Modulated by a Single Dose of the Monoamine Neurotransmission Enhancers Fluoxetine and Fenozolone during Hand Sensorimotor Tasks. Journal of Cerebral Blood Flow and Metabolism, 1999, 19, 1365-1375.	2.4	70
87	Perampanel, an AMPA antagonist, found to have no benefit in reducing â€œoffâ€•time in Parkinson's disease. Movement Disorders, 2012, 27, 284-288.	2.2	68
88	Amantadine in the treatment of Parkinson's disease and other movement disorders. Lancet Neurology, The, 2021, 20, 1048-1056.	4.9	67
89	Parkinson's disease and weight loss: A study with anthropometric and nutritional assessment. Clinical Autonomic Research, 1992, 2, 153-157.	1.4	66
90	Safety and tolerability of growth hormone therapy in multiple system atrophy: A double-blind, placebo-controlled study. Movement Disorders, 2007, 22, 1138-1144.	2.2	66

#	Article	IF	Citations
91	The improvement of movement and speech during rapid eye movement sleep behaviour disorder in multiple system atrophy. Brain, 2011, 134, 856-862.	3.7	66
92	The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model. Movement Disorders, 2014, 29, 1074-1079.	2.2	66
93	Multiple System Atrophy: Recent Developments and Future Perspectives. Movement Disorders, 2019, 34, 1629-1642.	2.2	65
94	Safety and efficacy of perampanel in advanced Parkinson's disease: A randomized, placebo-controlled study. Movement Disorders, 2010, 25, 896-905.	2.2	63
95	Nociceptive brain activation in patients with neuropathic pain related to Parkinson's disease. Parkinsonism and Related Disorders, 2013, 19, 548-552.	1.1	62
96	Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study. Movement Disorders, 2006, 21, 2110-2115.	2.2	61
97	Efficacy and safety of amantadine for the treatment of l-DOPA-induced dyskinesia. Journal of Neural Transmission, 2018, 125, 1237-1250.	1.4	61
98	Trial designs used to study neuroprotective therapy in Parkinson's disease. Movement Disorders, 2013, 28, 86-95.	2.2	59
99	Falls in ambulatory non-demented patients with Parkinsonâ€™s disease. Journal of Neural Transmission, 2015, 122, 1447-1455.	1.4	55
100	Factors related to orthostatic hypotension in Parkinson's disease. Parkinsonism and Related Disorders, 2012, 18, 501-505.	1.1	54
101	A Phase 1 Randomized Trial of Specific Active <scp>Î±â€Synuclein</scp> Immunotherapies <scp>PD01A</scp> and <scp>PD03A</scp> in Multiple System Atrophy. Movement Disorders, 2020, 35, 1957-1965.	2.2	53
102	The Movement Disorders task force review of dysautonomia rating scales in Parkinson's disease with regard to symptoms of orthostatic hypotension. Movement Disorders, 2011, 26, 1985-1992.	2.2	52
103	Minimal Clinically Important Difference in Parkinsonâ€™s Disease as Assessed in Pivotal Trials of Pramipexole Extended Release. Parkinson's Disease, 2014, 2014, 1-8.	0.6	51
104	Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinsonâ€™s disease. Brain, 2015, 138, 1271-1283.	3.7	51
105	Influence of Age, Circadian and Homeostatic Processes on Inhibitory Motor Control: A Go/Nogo Task Study. PLoS ONE, 2012, 7, e39410.	1.1	51
106	Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: A 6-month, randomized, placebo-controlled study. Movement Disorders, 2003, 18, 418-425.	2.2	50
107	Perampanel in Parkinson Disease Fluctuations. Clinical Neuropharmacology, 2012, 35, 15-20.	0.2	50
108	Methylphenidate modulates cerebral post-stroke reorganization. NeuroImage, 2006, 33, 913-922.	2.1	49

#	Article	IF	Citations
109	Disease progression and prognostic factors in multiple system atrophy: A prospective cohort study. Neurobiology of Disease, 2020, 139, 104813.	2.1	49
110	Selective serotonin reuptake inhibitor paroxetine modulates motor behavior through practice. A double-blind, placebo-controlled, multi-dose study in healthy subjects. Neuropsychologia, 2002, 40, 1815-1821.	0.7	47
111	Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis. Journal of the American Medical Directors Association, 2015, 16, 898.e1-898.e7.	1.2	46
112	Dyskinesia: L-Dopa-Induced and Tardive Dyskinesia. Clinical Neuropharmacology, 2001, 24, 313-323.	0.2	45
113	Longâ€term effects of rasagiline and the natural history of treated Parkinson's disease. Movement Disorders, 2016, 31, 1489-1496.	2.2	45
114	Levodopa monotherapy can induce "sleep attacks" in Parkinson's disease patients. Journal of Neurology, 2001, 248, 426-427.	1.8	44
115	Adverse Drug Reactions to Selegiline[colon] A Review of the French Pharmacovigilance Database. Clinical Neuropharmacology, 2000, 23, 271-275.	0.2	43
116	Skin cancer and Parkinson's disease. Movement Disorders, 2010, 25, 139-148.	2.2	43
117	Lâ€<scp>DOPA</scp>â€induced dyskinesias, motor fluctuations and healthâ€related quality of life: the <scp>COPARK</scp> survey. European Journal of Neurology, 2017, 24, 1532-1538.	1.7	43
118	Rotigotine transdermal delivery for the treatment of Parkinson's disease. Expert Opinion on Pharmacotherapy, 2009, 10, 677-691.	0.9	41
119	Subjective sleep dysfunction and insomnia symptoms in Parkinson's disease: Insights from a cross-sectional evaluation of the French CoPark cohort. Parkinsonism and Related Disorders, 2015, 21, 1323-1329.	1.1	40
120	Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson Disease. CNS Drugs, 2016, 30, 703-717.	2.7	40
121	Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease. Neurology, 2018, 90, e1849-e1857.	1.5	40
122	??2-Adrenoceptor Antagonists. CNS Drugs, 1998, 10, 189-207.	2.7	39
123	Clinical Features and Disease Haplotypes of Individuals With the N279K tau Gene Mutation. Archives of Neurology, 2002, 59, 943.	4.9	39
124	Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study. Parkinsonism and Related Disorders, 2021, 83, 79-85.	1.1	39
125	Rationale for delayedâ€start study of pramipexole in Parkinson's disease: The PROUD study. Movement Disorders, 2010, 25, 1627-1632.	2.2	38
126	Pardoprunox in early Parkinson's disease: Results from 2 large, randomized doubleâ€blind trials. Movement Disorders, 2011, 26, 1464-1476.	2.2	38

#	Article	IF	Citations
127	Clinical and economic analysis of spa therapy in Parkinson's disease. Movement Disorders, 2003, 18, 578-584.	2.2	37
128	Suggestive association between OPRM1 and impulse control disorders in Parkinson's disease. Movement Disorders, 2018, 33, 1878-1886.	2.2	37
129	Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy. Movement Disorders, 1998, 13, 673-676.	2.2	36
130	Efficacy, safety, and tolerability of overnight switching from immediateâ€•to once daily extendedâ€•release pramipexole in early Parkinson's disease. Movement Disorders, 2010, 25, 2326-2332.	2.2	36
131	Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients. Expert Opinion on Drug Safety, 2014, 13, 351-360.	1.0	35
132	Young-Onset Parkinson Disease With and Without Parkin Gene Mutations. Archives of Neurology, 2003, 60, 713.	4.9	35
133	Hereditary ferritinopathy. Journal of the Neurological Sciences, 2003, 207, 110-111.	0.3	34
134	Confinement and Sleep Deprivation Effects on Propensity to Take Risks. Aviation, Space, and Environmental Medicine, 2009, 80, 73-80.	0.6	34
135	Cannabis smoking impairs driving performance on the simulator and real driving: a randomized, doubleâ€blind, placeboâ€controlled, crossover trial. Fundamental and Clinical Pharmacology, 2018, 32, 558-570.	1.0	34
136	Tesofensine (NS 2330), a Monoamine Reuptake Inhibitor, in Patients With Advanced Parkinson Disease and Motor Fluctuations. Archives of Neurology, 2008, 65, 577.	4.9	32
137	Doubleâ€blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease. Movement Disorders, 2010, 25, 738-746.	2.2	32
138	Defining a minimal clinically relevant difference for the unified Parkinson's rating scale: An important but still unmet need. Movement Disorders, 2006, 21, 1059-1061.	2.2	31
139	Can Autonomic Testing and Imaging Contribute to the Early Diagnosis of Multiple System Atrophy? A Systematic Review and Recommendations by the <scp>Movement Disorder Society</scp> Multiple System Atrophy Study Group. Movement Disorders Clinical Practice, 2020, 7, 750-762.	0.8	31
140	A randomized, double-blind study of a skin patch of a dopaminergic agonist, piribedil, in Parkinson's disease. Movement Disorders, 1999, 14, 336-341.	2.2	30
141	Cortical motor activation in akinetic schizophrenic patients: A pilot functional MRI study. Movement Disorders, 2004, 19, 83-90.	2.2	30
142	Efficacy and Safety of Extended- Versus Immediate-Release Pramipexole in Japanese Patients With Advanced and L-dopaâ€“Undertreated Parkinson Disease. Clinical Neuropharmacology, 2012, 35, 174-181.	0.2	30
143	Examining the Reserve Hypothesis in Parkinson's Disease: A Longitudinal Study. Movement Disorders, 2019, 34, 1663-1671.	2.2	30
144	Drugs Associated With Restless Legs Syndrome. Journal of Clinical Psychopharmacology, 2012, 32, 824-827.	0.7	29

#	Article	IF	Citations
145	An original pharmacoepidemiologicalâ€“pharmacodynamic method: application to antipsychoticâ€induced movement disorders. British Journal of Clinical Pharmacology, 2017, 83, 612-622.	1.1	29
146	Safety and Tolerability of Active Immunotherapy Targeting Î±-Synuclein with PD03A in Patients with Early Parkinsonâ€™s Disease: A Randomized, Placebo-Controlled, Phase 1 Study. Journal of Parkinson's Disease, 2021, 11, 1079-1089.	1.5	29
147	Rasagiline in the pharmacotherapy of Parkinsonâ€™s disease â€“ a review. Expert Opinion on Pharmacotherapy, 2005, 6, 2061-2075.	0.9	28
148	Multiple system atrophy: A prototypical synucleinopathy for disease-modifying therapeutic strategies. Neurobiology of Disease, 2014, 67, 133-139.	2.1	28
149	A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia. Movement Disorders, 2016, 31, 1049-1054.	2.2	28
150	A proofâ€ofâ€concept, randomized, placeboâ€controlled, multiple crossâ€overs (nâ€ofâ€1) study of naftazone in Parkinsonâ€™s disease. Fundamental and Clinical Pharmacology, 2012, 26, 557-564.	1.0	27
151	Simvastatin decreases levodopa-induced dyskinesia in monkeys, but not in a randomized, placebo-controlled, multiple cross-over (â€œn-of-1â€) exploratory trial of simvastatin against levodopa-induced dyskinesia in Parkinson's disease patients. Parkinsonism and Related Disorders, 2013, 19, 416-421.	1.1	27
152	Inhaled levodopa in Parkinson's disease patients with OFF periods: A randomized 12-month pulmonary safety study. Parkinsonism and Related Disorders, 2020, 71, 4-10.	1.1	26
153	Impact of Subthalamic Deep Brain Stimulation on Impulse Control Disorders in Parkinson's Disease: A Prospective Study. Movement Disorders, 2021, 36, 750-757.	2.2	26
154	Safety of rasagiline for the treatment of Parkinson's disease. Expert Opinion on Drug Safety, 2011, 10, 633-643.	1.0	25
155	The safety and efficacy of safinamide mesylate for the treatment of Parkinsonâ€™s disease. Expert Review of Neurotherapeutics, 2016, 16, 245-258.	1.4	25
156	Safety Profile of Opicapone in the Management of Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2019, 9, 733-740.	1.5	25
157	Assessment of the Scopa-Aut questionnaire in multiple system atrophy: Relation to UMSARS scores and progression over time. Parkinsonism and Related Disorders, 2012, 18, 612-615.	1.1	24
158	Current Concepts in the Treatment of Multiple System Atrophy. Movement Disorders Clinical Practice, 2015, 2, 6-16.	0.8	24
159	A study of tolerance to apomorphine. British Journal of Pharmacology, 1996, 117, 781-786.	2.7	23
160	A Pharmacoeconomic Evaluation of Botulinum Toxin in the Treatment of Spasmodic Torticollis. Clinical Neuropharmacology, 2000, 23, 203-207.	0.2	23
161	Do Parkinsonâ€™s disease patients disclose their adverse events spontaneously?. European Journal of Clinical Pharmacology, 2012, 68, 857-865.	0.8	23
162	Atropinic (Anticholinergic) Burden in Parkinson's Disease. Movement Disorders, 2016, 31, 632-636.	2.2	23

#	Article	IF	Citations
163	Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting. Neurology, 2018, 90, 74-82.	1.5	23
164	How to diagnose parkinsonian central pain?. Parkinsonism and Related Disorders, 2019, 64, 50-53.	1.1	22
165	A French survey on the lockdown consequences of COVID-19 pandemic in Parkinson's disease. The ERCOPARK study. Parkinsonism and Related Disorders, 2021, 89, 128-133.	1.1	22
166	Orodispersible sublingual piribedil to abort OFF episodes: A single dose placeboâ€controlled, randomized, doubleâ€blind, crossâ€over study. Movement Disorders, 2010, 25, 368-376.	2.2	21
167	Longitudinal one-year study of levels and stoichiometry of neurofilament heavy and light chain concentrations in CSF in patients with multiple system atrophy. Journal of the Neurological Sciences, 2009, 279, 76-79.	0.3	20
168	Rotigotine transdermal patch for the treatment of Parkinsonâ€™s Disease. Fundamental and Clinical Pharmacology, 2013, 27, 81-95.	1.0	20
169	A Pilot Study of Stiripentol, a new Anticonvulsant Drug, in Complex Partial Seizures Uncontrolled by Carbamazepine. Clinical Neuropharmacology, 1989, 12, 119-123.	0.2	19
170	Dopaminagonists and fibrotic valvular heart disease: Further considerations. Movement Disorders, 2004, 19, 1524-1525.	2.2	19
171	Adverse drug reactions to dopamine agonists: A comparative study in the french pharmacovigilance database. Movement Disorders, 2010, 25, 1876-1880.	2.2	19
172	Pramipexole for the treatment of early Parkinsonâ€™s disease. Expert Review of Neurotherapeutics, 2011, 11, 925-935.	1.4	19
173	Espresso Coffee for the Treatment of Somnolence in Parkinsonâ€™s Disease: Results of n-of-1 Trials. Frontiers in Neurology, 2016, 7, 27.	1.1	19
174	Skin cancers and precancerous lesions in Parkinson's disease patients. Movement Disorders, 2007, 22, 1471-1475.	2.2	18
175	The Unified Multiple System Atrophy Rating Scale: Intrarater reliability. Movement Disorders, 2012, 27, 1683-1685.	2.2	18
176	Clinical Rating Scales for Urinary Symptoms in Parkinson Disease: Critique and Recommendations. Movement Disorders Clinical Practice, 2018, 5, 479-491.	0.8	18
177	Dopamine transporter imaging for the diagnosis of multiple system atrophy cerebellar type. Parkinsonism and Related Disorders, 2019, 63, 199-203.	1.1	18
178	Fluoxetine for the Symptomatic Treatment of Multiple System Atrophy: The MSAâ€FLUO Trial. Movement Disorders, 2021, 36, 1704-1711.	2.2	18
179	Glia Imaging Differentiates Multiple System Atrophy from Parkinson's Disease: A Positron Emission Tomography Study with [<scp>¹¹C</scp>]<scp>PBR28</scp> and Machine Learning Analysis. Movement Disorders, 2022, 37, 119-129.	2.2	18
180	COMT Inhibitors in the Management of Parkinsonâ€™s Disease. CNS Drugs, 2022, 36, 261-282.	2.7	18

#	Article	IF	Citations
181	Î±2-Adrenergic Sensitivity in ParkinsonÊ¼s Disease. Clinical Neuropharmacology, 1989, 12, 138-144.	0.2	17
182	Contrasting Changes in Cortical Activation Induced by Acute High-Frequency Stimulation within the Globus Pallidus in Parkinson's Disease. Journal of Cerebral Blood Flow and Metabolism, 2009, 29, 235-243.	2.4	17
183	Combined cardiovascular and sweating autonomic testing to differentiate multiple system atrophy from Parkinson's disease. Neurophysiologie Clinique, 2018, 48, 103-110.	1.0	17
184	Axial motor clues to identify atypical parkinsonism: A multicentre European cohort study. Parkinsonism and Related Disorders, 2018, 56, 33-40.	1.1	17
185	Redefining the strategy for the use of COMT inhibitors in Parkinsonâ€™s disease: the role of opicapone. Expert Review of Neurotherapeutics, 2021, 21, 1019-1033.	1.4	17
186	A Randomized, <scp>Doubleâ€Blind</scp>, Controlled Phase <scp>II</scp> Study of Foliglurax in Parkinson's Disease. Movement Disorders, 2022, 37, 1088-1093.	2.2	17
187	LRP10 in Î±-synucleinopathies. Lancet Neurology, The, 2018, 17, 1034.	4.9	16
188	Cerebrospinal Fluid Levels of Kininogenâ€1 Indicate Early Cognitive Impairment in Parkinson's Disease. Movement Disorders, 2020, 35, 2101-2106.	2.2	16
189	Broad white matter impairment in multiple system atrophy. Human Brain Mapping, 2021, 42, 357-366.	1.9	16
190	Shared Genetics of Multiple System Atrophy and Inflammatory Bowel Disease. Movement Disorders, 2021, 36, 449-459.	2.2	16
191	<scp>Onâ€Demand</scp> Therapy for <scp>OFF</scp> Episodes in Parkinson's Disease. Movement Disorders, 2021, 36, 2244-2253.	2.2	16
192	Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: Pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study. Movement Disorders, 2004, 19, 1006-1011.	2.2	15
193	Naftazone in advanced Parkinson's disease: An acute L-DOPA challenge randomized controlled trial. Parkinsonism and Related Disorders, 2019, 60, 51-56.	1.1	15
194	Brain <scp>5â€HT1A</scp> Receptor Binding in Multiple System Atrophy: An [<scp>¹⁸F</scp>]â€<scp>MPPF PET</scp> Study. Movement Disorders, 2021, 36, 246-251.	2.2	15
195	Cardiovascular effects of central injection of acetylcholine in anaesthetized dogs: a role for vasopressin release. British Journal of Pharmacology, 1990, 100, 471-476.	2.7	14
196	Pergolide. Clinical Neuropharmacology, 2005, 28, 120-125.	0.2	14
197	Assessment of quality of life with the multiple system atrophy healthâ€related quality of life scale. Movement Disorders, 2012, 27, 1574-1577.	2.2	14
198	Challenges and Perspectives in the Management of Late-Stage Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2020, 10, S75-S83.	1.5	14

#	Article	IF	Citations
199	Prevention and therapeutic strategies for levodopa-induced dyskinesias in ParkinsonÊ¼s disease. Current Opinion in Neurology, 2000, 13, 431-436.	1.8	13
200	Migraine Attacks Induced by Subcutaneous Apomorphine in Two Migrainous Parkinsonian Patients. Clinical Neuropharmacology, 1990, 13, 264-267.	0.2	12
201	New Directions in the Drug Treatment of Parkinson??s Disease. Drugs and Aging, 1996, 9, 169-184.	1.3	12
202	A Study of Dopaminergic Sensitivity in Parkinson's Disease: Comparison in â€œDe Novoâ€•and Levodopa-Treated Patients. Clinical Neuropharmacology, 1996, 19, 420-427.	0.2	11
203	Ergot and non-ergot dopamine agonists and heart failure in patients with Parkinsonâ€™s disease. European Journal of Clinical Pharmacology, 2017, 73, 99-103.	0.8	11
204	Opicapone for the management of end-of-dose motor fluctuations in patients with Parkinsonâ€™s disease treated with L-DOPA. Expert Review of Neurotherapeutics, 2017, 17, 649-659.	1.4	11
205	Critical appraisal of clinical trials in multiple system atrophy: Toward better quality. Movement Disorders, 2017, 32, 1356-1364.	2.2	11
206	LRP10 in Î±-synucleinopathies. Lancet Neurology, The, 2018, 17, 1033-1034.	4.9	11
207	Utilization Patterns of Amantadine in Parkinsonâ€™s Disease Patients Enrolled in the French COPARK Study. Drugs and Aging, 2020, 37, 215-223.	1.3	11
208	Î²-Adrenoceptor Drugs and Parkinsonâ€™s Disease: A Nationwide Nested Caseâ€“Control Study. CNS Drugs, 2020, 34, 763-772.	2.7	11
209	Monoamine oxidase inhibitorsâ€”is it time to up the TEMPO?. Lancet Neurology, The, 2003, 2, 142-143.	4.9	10
210	Serotonin reuptake inhibitors for depression in PD. Nature Reviews Neurology, 2012, 8, 365-366.	4.9	10
211	Droxidopa for the treatment of neurogenic orthostatic hypotension in neurodegenerative diseases. Expert Opinion on Pharmacotherapy, 2019, 20, 635-645.	0.9	10
212	Parkinson's disease polygenic risk score is not associated with impulse control disorders: A longitudinal study. Parkinsonism and Related Disorders, 2020, 75, 30-33.	1.1	10
213	Lack of Correlation Between Plasma Levels of Amitriptyline (and Nortriptyline) and Clinical Improvement of Chronic Pain of Peripheral Neurologic Origin. Clinical Neuropharmacology, 1987, 10, 560-564.	0.2	9
214	A Cross-Sectional Study on Drug Use in Multiple System Atrophy. CNS Drugs, 2014, 28, 483-490.	2.7	9
215	Tamoxifen and the risk of Parkinsonism: a case/non-case study. European Journal of Clinical Pharmacology, 2018, 74, 1181-1184.	0.8	9
216	French validation of the questionnaire for Impulsive-Compulsive Disorders in Parkinson's Diseaseâ€“Rating Scale (QUIP-RS). Parkinsonism and Related Disorders, 2019, 63, 117-123.	1.1	9

#	Article	IF	Citations
217	Involvement of a pertussis toxinâ€sensitive Gâ€protein in the pharmacological properties of septoâ€hippocampal neurones. British Journal of Pharmacology, 1989, 96, 956-960.	2.7	8
218	Pramipexole extended-release (once-daily formulation) for the treatment of Parkinson's disease. Expert Opinion on Pharmacotherapy, 2010, 11, 2221-2230.	0.9	8
219	The Parkinsonâ€™s Real-World Impact Assessment (PRISM) Study: A European Survey of the Burden of Parkinsonâ€™s Disease in Patients and their Carers. Journal of Parkinson's Disease, 2021, 11, 1309-1323.	1.5	8
220	Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies. Parkinsonism and Related Disorders, 2022, 96, 65-73.	1.1	8
221	Extended-release carbidopa-levodopa in Parkinson's disease. Lancet Neurology, The, 2013, 12, 325-326.	4.9	7
222	Distinctive Features of NREM Parasomnia Behaviors in Parkinsonâ€™s Disease and Multiple System Atrophy. PLoS ONE, 2015, 10, e0120973.	1.1	7
223	Mortality and Antipsychotic Drug Use in Elderly Patients With Parkinson Disease in Nursing Homes. Journal of the American Medical Directors Association, 2017, 18, 791-796.	1.2	7
224	Reversible myoclonusâ€ataxia encephalitis related to antiâ€mGLUR1 autoantibodies. Movement Disorders, 2019, 34, 438-439.	2.2	7
225	Parkinsonâ€™s Disease Drug Development Since 1999: A Story of Repurposing and Relative Success. Journal of Parkinson's Disease, 2021, 11, 421-429.	1.5	7
226	Dopamine agonists. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 84, 73-92.	1.0	6
227	The â€œLong and Winding Roadâ€•of the Diseaseâ€Modifying Effects of Levodopa Has Not Ended Yet. Movement Disorders, 2020, 35, 397-399.	2.2	6
228	Therapeutic strategies for Parkinsonâ€™s disease: promising agents in early clinical development. Expert Opinion on Investigational Drugs, 2020, 29, 1249-1267.	1.9	6
229	Personality dimensions of patients can change during the course of parkinsonâ€™s disease. PLoS ONE, 2021, 16, e0245142.	1.1	5
230	Thought disorders among non-demented outpatients with Parkinsonâ€™s disease: prevalence and associated factors. Journal of Neural Transmission, 2010, 117, 1183-1188.	1.4	4
231	Jejunal levodopa infusion in Parkinson's disease. Lancet Neurology, The, 2014, 13, 128-129.	4.9	4
232	Descriptive analysis of the French NS-Park registry: Towards a nation-wide Parkinson's disease cohort?. Parkinsonism and Related Disorders, 2019, 64, 226-234.	1.1	4
233	Personality Dimensions Are Associated with Quality of Life in Fluctuating Parkinsonâ€™s Disease Patients (PSYCHO-STIM). Journal of Parkinson's Disease, 2020, 10, 1-9.	1.5	4
234	The management of patients with early Parkinson's disease. Advances in Neurology, 2003, 91, 203-11.	0.8	4

#	Article	IF	Citations
235	Adrenal Catecholamine Concentration After Domperidone. Clinical Neuropharmacology, 1987, 10, 479-481.	0.2	3
236	Droxidopa for the treatment of neurogenic orthostatic hypotension and other symptoms of neurodegenerative disorders. Expert Opinion on Orphan Drugs, 2014, 2, 509-522.	0.5	3
237	Excessive buccal saliva in patients with Parkinsonâ€™s disease of the French COPARK cohort. Journal of Neural Transmission, 2020, 127, 1607-1617.	1.4	3
238	Assessment of plasma creatine kinase as biomarker for levodopa-induced dyskinesia in Parkinsonâ€™s disease. Journal of Neural Transmission, 2019, 126, 789-793.	1.4	2
239	CVT-301 for Parkinson's disease: dose and effect size issues. Lancet Neurology, The, 2019, 18, 128-130.	4.9	2
240	Preoperative REM Sleep Behavior Disorder and Subthalamic Nucleus Deep Brain Stimulation Outcome in Parkinson Disease 1 Year After Surgery. Neurology, 2021, 97, e1994-e2006.	1.5	2
241	Orthostatic hypotension in Parkinsonâ€™s disease. Neurodegenerative Disease Management, 2013, 3, 363-377.	1.2	1
242	Can a new trial end controversy over when to use levodopa?. Nature Reviews Neurology, 2014, 10, 488-489.	4.9	1
243	Pharmacological Insights into Levodopaâ€induced Motor Fluctuations in Patients with Parkinson's Disease. Movement Disorders Clinical Practice, 2016, 3, 523-526.	0.8	1
244	Impact of current antipsychotic medications on comparative mortality and adverse events in people with Parkinsonâ€™s disease psychosis (PDP). Parkinsonism and Related Disorders, 2016, 22, e91-e92.	1.1	1
245	Evaluation of Prescription Practices of Domperidone in Parkinsonâ€™s Disease: A Cross Sectional Study Among French Neurologists. CNS Drugs, 2020, 34, 1267-1274.	2.7	1
246	Opicapone for Parkinsonâ€™s disease: clinical evidence and future perspectives. Neurodegenerative Disease Management, 2021, 11, 193-206.	1.2	1
247	Strat??gies pharmacoth??rapeutiques actuelles et futures dans la prise en charge de la maladie de Parkinson. Disease Management and Health Outcomes, 2001, 9, 31-39.	0.3	1
248	Clinical Trials for in Parkinsonâ€™s. Neuromethods, 2021, , 109-135.	0.2	1
249	Rotigotine Transdermal Patch for the Treatment of Restless Legs Syndrome. Integrative Medicine International, 2014, 1, 32-43.	0.6	0
250	What Strategy Should France Implement for H2020?. Therapie, 2015, 70, 103-109.	0.6	0
251	PANDA: Prolonged release oxycodone/naloxone (OXN PR) for severe Parkinsonâ€™s disease (PD)-related pain. Parkinsonism and Related Disorders, 2016, 22, e101-e102.	1.1	0
252	Rotigotine for the Treatment of Advanced Parkinson's Disease. European Neurological Review, 2009, 4, 24.	0.5	0